본문으로 건너뛰기
← 뒤로

Double refractory chronic lymphocytic leukemia: clinical scenarios and therapeutic strategies.

1/5 보강
Medicina clinica 📖 저널 OA 0% 2021: 0/2 OA 2023: 0/1 OA 2024: 0/2 OA 2025: 0/4 OA 2026: 0/9 OA 2021~2026 2026 Vol.166(1) p. 107288
Retraction 확인
출처

Mozas P, Quintela D, Serna Á

ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 44.0%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도

📝 환자 설명용 한 줄

Despite its typically indolent course in most patients, chronic lymphocytic leukemia (CLL) can relapse or become refractory to the two main classes of drugs commonly used: covalent BTK inhibitors and

이 논문을 인용하기

↓ .bib ↓ .ris
APA Mozas P, Quintela D, Serna Á (2026). Double refractory chronic lymphocytic leukemia: clinical scenarios and therapeutic strategies.. Medicina clinica, 166(1), 107288. https://doi.org/10.1016/j.medcli.2025.107288
MLA Mozas P, et al.. "Double refractory chronic lymphocytic leukemia: clinical scenarios and therapeutic strategies.." Medicina clinica, vol. 166, no. 1, 2026, pp. 107288.
PMID 41538902 ↗

Abstract

Despite its typically indolent course in most patients, chronic lymphocytic leukemia (CLL) can relapse or become refractory to the two main classes of drugs commonly used: covalent BTK inhibitors and BCL2 inhibitors. This review outlines the potential reasons for discontinuation of these drug classes, defines the concepts of double exposure (DE) and double refractoriness (DR), delineates the possible treatment sequences leading to DR, summarizes the poor prognosis of this patient subgroup, and describes the approved, investigational, and less optimal therapeutic alternatives for the management of this population. Finally, three illustrative clinical vignettes of patients with DE/DR CLL are presented, including case analysis and practical management recommendations, as well as teaching points.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

… 외 6개

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반